Skip to main content

Table 2 Adverse events

From: Camrelizumab combined with apatinib plus irinotecan as a second-line treatment in advanced or metastatic esophageal squamous cell carcinoma patients

Adverse events, n (%)

Any grade

Grade I

Grade II

Grade III

Grade IV

Leukopenia

31 (52.5)

11 (18.6)

14 (23.7)

3 (5.1)

3 (5.1)

Fatigue

15 (25.4)

12 (20.3)

2 (3.4)

1 (1.7)

0 (0.0)

Anemia

14 (23.7)

10 (16.9)

4 (6.8)

0 (0.0)

0 (0.0)

Thrombocytopenia

14 (23.7)

8 (13.6)

4 (6.8)

2 (3.4)

0 (0.0)

Neutropenia

13 (22.0)

6 (10.2)

5 (8.5)

1 (1.7)

1 (1.7)

Hypoalbuminemia

13 (22.0)

13 (22.0)

0 (0.0)

0 (0.0)

0 (0.0)

Myelosuppression

12 (20.3)

1 (1.7)

9 (15.3)

0 (0.0)

2 (3.4)

Loss of appetite

10 (16.9)

6 (10.2)

3 (5.1)

1 (1.7)

0 (0.0)

Erythropenia

10 (16.9)

5 (8.5)

3 (5.1)

0 (0.0)

2 (3.4)

Digestive tract reaction

8 (13.6)

6 (10.2)

2 (3.4)

0 (0.0)

0 (0.0)

Increased TBIL

8 (13.6)

6 (10.2)

2 (3.4)

0 (0.0)

0 (0.0)

Diarrhea

8 (13.6)

3 (5.1)

2 (3.4)

3 (5.1)

0 (0.0)

Liver dysfunction

7 (11.9)

4 (6.8)

3 (5.1)

0 (0.0)

0 (0.0)

Increased AST

6 (10.2)

4 (6.8)

2 (3.4)

0 (0.0)

0 (0.0)

RCCEP

5 (8.5)

5 (8.5)

0 (0.0)

0 (0.0)

0 (0.0)

Increased ALT

5 (8.5)

4 (6.8)

1 (1.7)

0 (0.0)

0 (0.0)

Lymphopenia

5 (8.5)

4 (6.8)

1 (1.7)

0 (0.0)

0 (0.0)

Weight loss

5 (8.5)

4 (6.8)

1 (1.7)

0 (0.0)

0 (0.0)

Increased blood pressure

4 (6.8)

2 (3.4)

2 (3.4)

0 (0.0)

0 (0.0)

Hand-foot skin reaction

4 (6.8)

2 (3.4)

1 (1.7)

1 (1.7)

0 (0.0)

Nausea and vomiting

3 (5.1)

1 (1.7)

2 (3.4)

0 (0.0)

0 (0.0)

Increased Cr

3 (5.1)

3 (5.1)

0 (0.0)

0 (0.0)

0 (0.0)

Hypocalcemia

2 (3.4)

2 (3.4)

0 (0.0)

0 (0.0)

0 (0.0)

Hypothyroidism

2 (3.4)

1 (1.7)

1 (1.7)

0 (0.0)

0 (0.0)

Fever

2 (3.4)

2 (3.4)

0 (0.0)

0 (0.0)

0 (0.0)

Sore throat

1 (1.7)

1 (1.7)

0 (0.0)

0 (0.0)

0 (0.0)

Gastrointestinal bleeding

2 (3.4)

0 (0.0)

2 (3.4)

0 (0.0)

0 (0.0)

Hemoptysis

1 (1.7)

1 (1.7)

0 (0.0)

0 (0.0)

0 (0.0)

Oral mucosal inflammation

1 (1.7)

0 (0.0)

1 (1.7)

0 (0.0)

0 (0.0)

Immune enteritis

1 (1.7)

0 (0.0)

1 (1.7)

0 (0.0)

0 (0.0)

Pain

1 (1.7)

0 (0.0)

1 (1.7)

0 (0.0)

0 (0.0)

Atrial fibrillation

1 (1.7)

0 (0.0)

0 (0.0)

1 (1.7)

0 (0.0)

  1. TBIL, total bilirubin; AST, aspartate aminotransferase; RCCEP, reactive cutaneous capillary endothelial proliferation; ALT, alanine aminotransferase; Cr, creatinine